尿激酶胸腔注入治疗结核性胸膜炎疗效观察  

Therapeutic Effect of Urokinase Infusion on Tuberculous Pleurisy

作　　者：李永福[1] LI Yongfu(Chest Department,Heze Hospital of Infectious Diseases,HezeShandong 274029,China)

机构地区：[1]山东省菏泽市传染病医院胸科,山东菏泽274029

出　　处：《中国卫生标准管理》2019年第6期72-73,共2页China Health Standard Management

摘　　要：目的探讨结核性胸膜炎行胸腔注入尿激酶的治疗效果。方法对确诊患者102例,随机分为胸腔注射尿激酶(观察组)和未注射尿激酶组(对照组),均规范抗结核治疗和积极胸腔穿刺抽液,尿激酶注射组于每次抽液后用尿激酶10万IU加10 mL生理盐水溶解后注入胸膜腔。结果注射尿激酶组的抽液总量大于对照组,手术治疗的概率小于对照组。结论胸腔内注射尿激酶治疗结核性胸膜炎可以减少胸膜肥厚、黏连、分隔及包裹,一定程度上避免了不必要的手术治疗,缩短了治疗疗程,减轻了患者的痛苦,减少了患者的经济负担。Objective To investigate the therapeutic effect of intrathoracic injection of urokinase in tuberculous pleurisy.Methods 102 patients were diagnosed and randomly divided into pleural injection group and urokinase group(control group).All patients were treated with anti-tuberculosis treatment and active thoracic puncture.Urokinase injection group used urine after each pumping.The kinase 100,000 IU plus 10 mL of physiological saline was dissolved and injected into the pleural cavity.Results The total amount of fluid in the urokinase group was greater than that in the control group,and the probability of surgical treatment was significantly lower than that in the control group.Conclusion Intrathoracic injection of urokinase for tuberculous pleurisy can significantly reduce pleural thickening,adhesion,separation and encapsulation,avoiding unnecessary surgical treatment to some extent,shortening the course of treatment,reducing the suffering of patients and reducing the economics of patients.

关 键 词：注药 胸腔内 尿激酶 结核 渗出性胸膜炎 疗效 

分 类 号：R973[医药卫生—药品]